Jane Street
SGMT icon

Jane Street’s Sagimet Biosciences SGMT Stock Holding History

Jane Street’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-17,187
Closed -$117K – 12967
2026
Q1 		$89.8K Sell
17,187
-75,249
-81% -$419K ﹤0.01% 10699
2025
Q4 		$547K Buy
92,436
+79,595
+620% +$572K ﹤0.01% 7473
2025
Q3 		$88.1K Sell
12,841
-10,952
-46% -$88.8K ﹤0.01% 10187
2025
Q2 		$181K Sell
23,793
-4,073
-15% -$17.2K ﹤0.01% 8624
2025
Q1 		$90.8K Sell
27,866
-27,408
-50% -$115K ﹤0.01% 8851
2024
Q4 		$249K Buy
+55,274
New +$280K ﹤0.01% 8050
2024
Q3 		– Sell
-151,632
Closed -$519K – 10324
2024
Q2 		$519K Buy
151,632
+127,694
+533% +$586K ﹤0.01% 6961
2024
Q1 		$130K Buy
+23,938
New +$172K ﹤0.01% 8427

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Jane Street's SGMT Position: Q2 2026 in Review

Jane Street sold out of Sagimet Biosciences (SGMT) in Q2 2026, closing a stake of 17,187 shares — an estimated $117K sold.

Jane Street first reported a position in SGMT in Q1 2024 and held it in 8 quarters. The position peaked at $547K in Q4 2025. 122 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • Jane Street reported no remaining Sagimet Biosciences position as of Q2 2026 after selling out during the quarter.
  • Jane Street sold 17,187 Sagimet Biosciences shares in Q2 2026, an estimated $117K.
  • Jane Street first reported a position in Sagimet Biosciences in Q1 2024 and held it in 8 quarters.
  • Jane Street's Sagimet Biosciences position peaked at $547K in Q4 2025.
  • 122 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.